Hearing loss with oral chelators in thalassemia
نویسندگان
چکیده
منابع مشابه
Hearing loss in Iranian thalassemia major patients treated with deferoxamine: A systematic review and meta-analysis
Background: Hearing disorders are reported in thalassemia patients treated with deferoxamine. This study aimed to assess hearing loss in Iranian thalassemia major patients treated with deferoxamine. Methods: This review article was designed based on PRISMA guidelines. To review the literature, two researchers studied national and international databases including Iranmedex, Magiran, Medlib, SI...
متن کاملHearing Loss Related Quality of Life in Adolescents with Hearing Loss
Objectives: Quality of life, when referring to an individual’s health, is called health-related quality of life. The purpose of this study is to assess self-perceived hearing loss related quality of life of adolescents with hearing loss and its relationship with sex, age sub-groups or school settings with domains of quality of life. Methods: A school based survey was conducted in Tehra...
متن کاملThalassemia: cardiac iron and chelators.
1. Díez JJ, Iglesias P. The role of the novel adipocyte-derived hormone adiponectin in human disease. Eur J Endocrinol. 2003;148:293-300. 2. Leth H, Andersen KK, Frystyk J, Tarnow L, Rossing P, Paeving HH, et al. Elevated levels of high-molecularweight adiponectin in type 1 diabetes. J Clin Endocrinol Metab. 2008;93:3186-91. 3. Oh DK, Ciaraldi T, Henry RR. Adiponectin in health and disease. Dia...
متن کاملUpdate on iron chelators in thalassemia.
Over the past four decades, there have been dramatic improvements in survival for patients with thalassemia major due in large measure to improved iron chelators. Two chelators are approved for use in the United States and Canada, parenteral deferoxamine and oral deferasirox. Three are available in much of the rest of the world, where oral deferiprone is also approved (in the United States, def...
متن کاملOral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions.
For nearly 30 years, patients with transfusional iron overload have depended on nightly deferoxamine infusions for iron chelation. Despite dramatic gains in life expectancy in the deferoxamine era for patients with transfusion-dependent anemias, the leading cause of death for young adults with thalassemia major and related disorders has been cardiac disease from myocardial iron deposition. Stra...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Pediatric Hematology Oncology Journal
سال: 2019
ISSN: 2468-1245
DOI: 10.1016/j.phoj.2019.08.034